NASDAQ:GTHX
G1 Therapeutics Inc Stock News
$4.25
-0.0200 (-0.468%)
At Close: May 07, 2024
Nasdaq Rises 1.5%; G1 Therapeutics Shares Plummet
05:24pm, Monday, 13'th Feb 2023 Benzinga
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1.5% on Monday.
The Dow traded up 0.96% to 34,193.83 while the NASDAQ rose 1.52% to 11,896.75. The S&P 500 al
US Stocks Open Higher; Dow Jumps 200 Points
03:23pm, Monday, 13'th Feb 2023 Benzinga
U.S. stocks traded higher this morning, with the Dow Jones gaining around 200 points on Monday.
Following the market opening Monday, the Dow traded up 0.59% to 34,069.23 while the NASDAQ rose 0.65% to
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)
11:00am, Monday, 13'th Feb 2023 GlobeNewswire Inc.
- PRESERVE 1 Achieved its Co-Primary Endpoints Showing Statistically Significant Reductions in Occurrence of Severe Neutropenia During Induction and Duration of Severe Neutropenia in Cycles 1 Through
Pharma Stock Hits Record Low Due to Pulled Study
10:22am, Monday, 13'th Feb 2023
The shares of G1 Therapeutics Inc (NASDAQ:GTHX) were last seen down 53.6% at $3.33, after the company announced plans to discontinue a drug study for the treatment of a type of colon cancer , with pl
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:46pm, Wednesday, 01'st Feb 2023 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerc
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
03:00pm, Monday, 30'th Jan 2023 Benzinga
Upgrades
According to B of A Securities, the prior rating for Flowserve Corp (NYSE:FLS) was changed from Neutral to Buy. Flowserve earned $0.09 in the third quarter, compared to $0.29 in the year-ago
G1 Therapeutics: Poised For A Turnaround
05:22am, Saturday, 21'st Jan 2023 Seeking Alpha
G1 Therapeutics' shares have experienced much volatility in the past year. While it has tremendous risk as a speculative play, read why I rate GTHX stock a Buy.
G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference
12:00pm, Wednesday, 11'th Jan 2023 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 19th, 2023, at 11:30 AM EST
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
11:30am, Monday, 09'th Jan 2023 GlobeNewswire Inc.
- Initial Results from Pivotal Phase 3 PRESERVE 1 Trial in Colorectal Cancer Expected in February 2023; Positive Results Would Initiate Regulatory Interactions for Label Expansion -
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
03:01pm, Thursday, 05'th Jan 2023 Benzinga
Upgrades
For Algonquin Power & Utilities Corp (NYSE:AQN), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. In the third quarter, Algonquin Power showed an EPS of $0.11, compared
G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023
11:30am, Wednesday, 04'th Jan 2023 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided an initial update on PRESERVE 3, an ongoin
G1 Therapeutics to Participate in the 41st Annual J.P. Morgan Conference
07:00pm, Tuesday, 03'rd Jan 2023 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 11, 2023, at 1:30 PM PST, G
Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment
11:04pm, Wednesday, 07'th Dec 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided initial results from a 24 patient Phase 2
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:41am, Friday, 02'nd Dec 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerc
G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference
03:30pm, Wednesday, 23'rd Nov 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 23, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive Of